newsfilter
← Latest News
GlobeNewswire·

Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure

TORONTO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB:RVVTF) (CSE:RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of